SNORD114-16: A Potential Drug Target and Biomarker for Small Nucleolar RNA

Target Name: SNORD114-16

NCBI ID: G767594

SNORD114-16

Other Name(s): small nucleolar RNA, C/D box 114-16 | Small nucleolar RNA, C/D box 114-16 | 14q(II-16)

SNORD114-16: A Potential Drug Target and Biomarker for Small Nucleolar RNA

Small nucleolar RNA (snRNA) is a non-coding RNA molecule that plays a crucial role in the regulation of gene expression in eukaryotic cells. One of the key functional groups of snRNA is the C/D box, which is a region of the RNA molecule that contains a specific sequence of nucleotides. C/D box snRNA molecules are highly conserved across different species and are involved in various cellular processes, including DNA replication, transcription, and translation.

One of the most well-known C/D box snRNA molecules is SNORD114-16. This RNA molecule has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In this article, we will discuss the properties of SNORD114-16, its potential drug target status, and its potential as a biomarker for disease diagnosis and treatment.

Properties of SNORD114-16

SNORD114-16 is a 22-nt RNA molecule that contains a single exon. It has a calculated molecular weight of 18.8 kDa and a base composition of A=29, C=50, G=21, and U=4. The RNA molecule has a single RNA secondary structure, which is a hairpin loop.

The C/D box region of SNORD114-16 is a 12-nt sequence that contains the conserved C/D box motif. This motif consists of a specific core sequence of GAGCG, which is followed by a series of secondary motifs that include a 5'-terminal alpha-helix, a 3'-terminal beta-sheet, and a 2'-terminal loop. The C/D box region of SNORD114-16 is conserved across different species, and its presence suggests that it plays a critical role in the regulation of gene expression.

Potential Drug Target Status

SNORD114-16 has been identified as a potential drug target due to its unique C/D box structure and its involvement in various cellular processes. The C/D box region of SNORD114-16 is involved in the regulation of gene expression, and studies have shown that it plays a role in the development and progression of various diseases.

One of the potential mechanisms by which SNORD114-16 may be a drug target is its role in the regulation of cellular signaling pathways. Studies have shown that SNORD114-16 is involved in the regulation of several cellular signaling pathways, including the regulation of cell growth, cell differentiation, and cell survival. Additionally, studies have shown that SNORD114-16 is involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed.

SNORD114-16 has also been shown to play a role in the regulation of inflammation. Studies have shown that SNORD114-16 is involved in the regulation of inflammation-related signaling pathways, including the regulation of cytokine production and the regulation of immune cell function.

Potential Biomarker Status

SNORD114-16 has also been identified as a potential biomarker for various diseases. Its unique C/D box structure and its involvement in various cellular processes make it an attractive candidate for use as a biomarker.

One of the potential applications of SNORD114-16 as a biomarker is its ability to be targeted with small molecules. The C/D box region of SNORD114-16 is relatively stable, and this stability

Protein Name: Small Nucleolar RNA, C/D Box 114-16

The "SNORD114-16 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD114-16 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets